Bayer's Cardiology Offensive: New Data Points and a Diagnostic Wildcard Reshape the Investment Case

Bayer showcases new clinical data, strong Q2 results, and debt reduction, while Roundup settlement awaits final approval in September.

The weekend news flow from Leverkusen carried a clear strategic signal: Bayer is leaning harder into its pharmaceuticals division as the engine of future growth, with fresh clinical data landing across both therapeutic and diagnostic fronts. The centerpiece is the Phase III REVEAL study for the investigational PET radiotracer Iod-124-Evuzamitid, the results of which were unveiled on Sunday alongside new evidence that Kerendia slows kidney function decline in patients with hypertensive nephropathy.

The timing is deliberate. With the glyphosate litigation still casting a long shadow over the equity story, management is leaning into what it can control: a pipeline that is quietly broadening across multiple indications. The pattern was already visible last week. On Friday, Bayer filed for expanded approval of finerenone in Japan for chronic kidney disease, and just days earlier, on August 24, Hyrnuo received Japanese approval for HER2-mutated non-small cell lung cancer. Taken together, the regulatory cadence paints a picture of a pharma business gaining traction across therapy areas — a useful counterweight to the legal overhang from the crop science legacy.

The clinical presentation at the European Society of Cardiology congress in Munich was particularly substantive, with eleven oral presentations covering cardiovascular, renal, and stroke indications. The Kerendia data is more than an academic exercise. The drug has become a genuine growth engine for the pharma unit, with first-half 2026 sales jumping 75 percent to EUR 603 million. If the hypertensive nephropathy data broadens the label, the revenue base could widen considerably.

The Quarter That Backs the Narrative

These pipeline developments land on top of a second quarter that gave investors little to complain about. Group revenue reached EUR 10.87 billion, up 2.2 percent on a currency- and portfolio-adjusted basis, while adjusted EBITDA climbed to EUR 2.14 billion — comfortably ahead of the EUR 1.94 billion consensus. Crop Science also pulled its weight, with operating profit surging nearly 30 percent to EUR 902 million, helped by firmer glyphosate pricing and the US re-approval of dicamba herbicides.

Management used the results to reconfirm full-year guidance: adjusted EBITDA of EUR 9.6 to 10.1 billion and core earnings per share between EUR 4.30 and 4.90. The more notable adjustment came on the balance sheet side, where Bayer trimmed its expected net financial debt to EUR 29–30 billion, reflecting the EUR 3.0 billion equity injection tied to the Apollo deal announced in July. Under that transaction, Apollo takes a minority stake in a newly formed entity housing Bayer's contraception business, while Bayer retains majority ownership and operational control. Closing is expected in the third quarter.

Analysts Turn More Constructive

The combination of a strong pharma franchise, resilient crop protection, and a deleveraging trajectory has prompted several houses to lift their targets. UBS's Matthew Weston raised his price objective from EUR 52 to EUR 62 in early August, maintaining a buy rating and citing roughly 10 percent operational outperformance in the second quarter. Goldman Sachs' James Quigley followed suit, nudging his target from EUR 62.50 to EUR 63.50 while reaffirming a buy stance.

The stock has responded in kind. Monday's session saw the shares trade at EUR 49.10, up 0.9 percent from Friday's close, leaving the equity roughly 8.8 percent shy of the 52-week high of EUR 53.86 touched in early July. Year-to-date, the gain stands at 33 percent, with a 75 percent advance over twelve months — a reflection of the market's growing comfort with the operational story.

The Legal Calendar Still Matters

For all the clinical momentum, the Roundup litigation remains the wildcard. A US appeals court recently rejected plaintiffs' objections to Bayer's effort to conclude the USD 7.25 billion settlement, per Reuters. The final approval hearing, however, has been pushed to September 14 at the joint request of Monsanto and plaintiff counsel, who sought additional time to process opt-out applications.

The strategic picture is therefore a two-track affair: on the legal side, Bayer is working toward a binding resolution of the glyphosate claims; on the operational side, it is advancing multiple growth vectors simultaneously — Kerendia, Hyrnuo, and now a diagnostic candidate with the radiotracer. Should the settlement receive final approval next month, the planning certainty that follows would only sharpen the focus on what the pharma pipeline can deliver.